Respirology最新文献

{"title":"Obstructive Sleep Apnoea Treatments-Where Are We Now?","authors":"Steven Luu, Donald Lee, Brendon J Yee","doi":"10.1111/resp.70109","DOIUrl":"10.1111/resp.70109","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"920-922"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144848584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Historical and Contemporary Overview of Respiratory Nursing: Letter From The United States of America.","authors":"Kathleen O Lindell, Lynn F Reinke","doi":"10.1111/resp.70101","DOIUrl":"10.1111/resp.70101","url":null,"abstract":"<p><p>Special Series: Leading Women in Respiratory Clinical Sciences Series Editors: Anne-Marie Russel and Kathleen O Lindell.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"1005-1007"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upper Airway Control Therapy (U-ACT): The Development of a Non-Pharmacological Intervention for Inducible Laryngeal Obstruction.","authors":"Jemma Haines, Jaclyn A Smith, Stephen J Fowler, Janelle Yorke","doi":"10.1111/resp.70073","DOIUrl":"10.1111/resp.70073","url":null,"abstract":"<p><strong>Background and objective: </strong>Non-pharmacological intervention is the recommended gold standard for inducible laryngeal obstruction (ILO) treatment. Despite this, there is no standardised approach and interventions are poorly described. The objective was to develop and describe a standardised non-pharmacological intervention for ILO, for future testing of effectiveness.</p><p><strong>Methods: </strong>MRC guidelines for complex intervention development were followed; the methodological approach was structured using the INDEX principles. The multi-phase research stages were: (1) evidence review; (2) qualitative data collection from speech and language therapists (n = 7) and patients (n = 22); (3) intervention design and theoretical underpinning; (4) prototype survey feedback from Stage 2 participants; and (5) final intervention description, using a validated reporting framework.</p><p><strong>Results: </strong>Systematic review and synthesis of 14 studies (n = 527) identified key uncertainties and steered Stage 2 interviews. Framework analysis of qualitative data collected identified five overarching key themes for inclusion. The resulting 'Upper Airway Control Therapy' (U-ACT) intervention comprises two core components (education & empowerment; reliever breath control), four supporting components (bio-feedback training; prevention methods; supporting co-existing conditions; managing others' reactions to ILO) and a cross-cutting home practice component. U-ACT's mechanisms of action to bring about change includes 36 behaviour change techniques. Feedback on U-ACT protype was extremely positive; survey responders (n = 23; 87% response rate) strongly agreed to acceptability statements for all parameters surveyed [5-point Likert scale; median (range), 4.5, 3-5].</p><p><strong>Conclusion: </strong>The U-ACT intervention, developed with keystakeholders and underpinned with a programme theory, is fully manualised and ready for evaluation. If future testing proves clinical and cost effectiveness, it could be incorporated into existing ILO services.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"935-948"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Pneumothorax After Treatment With Endobronchial Valves: A Cohort Study.","authors":"Kirstine Hermann Jørgensen, Thomas Decker Christensen, Ingrid Louise Titlestad, Jesper Rømhild Davidsen, Kathrine Bock, Kristine Jensen, Morten Bendixen, Ole Dan Jørgensen, Michael Perch, Elisabeth Bendstrup","doi":"10.1111/resp.70069","DOIUrl":"10.1111/resp.70069","url":null,"abstract":"<p><strong>Background and objectives: </strong>Pneumothorax (PTX) is the most prevalent and serious adverse event associated with endobronchial valve (EBV) treatment in chronic obstructive pulmonary disease (COPD) with emphysema. This study aimed to compare preoperative characteristics and 30-day outcomes in patients with COPD with and without PTX.</p><p><strong>Method: </strong>This retrospective nationwide cohort study included patients treated with EBV between 2017 and 2023 at all EBV centres in Denmark. Data were retrieved from medical records.</p><p><strong>Results: </strong>A total of 228 patients were included, of whom 46 (20.2%) had PTX. The median time to PTX was 7 h (IQR 2-22) and the median drain treatment duration was 13 days (IQR 8.5-22). The risk of PTX was significantly higher when EBV treatment was performed in the upper lobes than in the lower lobes (adjusted RR 6.32, 95% CI 2.56-15.60). High target lobe volume (adjusted OR pr 100 mL increase 1.12, 95% CI 1.02-1.22) and high residual volume (adjusted OR pr 10%pt. increase 1.11, 95% CI 1.01-1.23) were independent risk factors for PTX. More PTX patients had atelectasis after 2 h compared to patients without PTX. The risk of pneumonia (RR 4.5, 95% CI 1.7-11.8), empyema (p = 0.0047) and ICU admission (RR 9.89, 95% CI 1.98-49.4) were significantly higher in the PTX patients than in the patients without PTX.</p><p><strong>Conclusions: </strong>PTX was more prevalent when EBV treatment was performed in the upper lobes and with high residual volume and target lobe volume, leading to prolonged hospital admission and risk of hospital-acquired pneumonia.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"979-986"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Clinical Scoring System Predicting 30-Day Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.","authors":"Joong-Yub Kim, Jayoun Kim, Myeong Geun Choi, Min Jee Kim, Yun Hae Ahn, Nakwon Kwak, Jaeyoung Cho, Jinwoo Lee, Young Sik Park, Chang-Hoon Lee, Sang-Min Lee, Chul-Gyu Yoo, Jin Woo Song, Sun Mi Choi","doi":"10.1111/resp.70071","DOIUrl":"10.1111/resp.70071","url":null,"abstract":"<p><strong>Background and objectives: </strong>Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a frequent and fatal complication of IPF, with highly variable individual outcomes that are challenging to predict.</p><p><strong>Methods: </strong>This study included patients (≥ 19 years) who met the diagnostic criteria for AE-IPF. The primary outcome was 30-day mortality following hospital admission. Data on commonly assessed parameters at the time of emergency room presentation or hospital admission were collected. Variable selection and scoring were performed using the LASSO method and multivariable logistic regression, and the resulting model was validated in an independent cohort.</p><p><strong>Results: </strong>The derivation and validation cohorts comprised 128 and 100 patients, respectively. The final model incorporated eight variables (points): age ≥ 69 years (1), smoking status (current smoker: 2, past smoker: 1), use of home oxygen (1), history of hospital admission for non-AE events within the past 6 months (1), body mass index < 18.5 or > 23 kg/m² (1), lymphocyte percentage < 19% (2), total protein < 6.5 g/dL (1) and lactate level ≥ 1.75 mmol/L (1). Patient scores were calculated by summing the points for each variable. This scoring system of total 10 points demonstrated good discrimination, with Harrell's C-statistics of 0.84 (95% confidence interval, 0.75-0.93) in the derivation cohort and 0.81 (95% confidence interval, 0.71-0.92) in the validation cohort, and performed well in predicting 2-week, 3-month and in-hospital mortality.</p><p><strong>Conclusion: </strong>We developed and validated a scoring system based on readily available clinical parameters that effectively stratified 30-day mortality risk in patients with AE-IPF, offering a practical tool for bedside prognosis.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"957-969"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"World Lung Day 2025-Healthy Lungs, Healthy Life.","authors":"Kwun M Fong, David C L Lam, Yoshinori Hasegawa, Suga Konno, Chul-Gyu Yoo","doi":"10.1111/resp.70121","DOIUrl":"10.1111/resp.70121","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"923-925"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145113567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter From Malaysia: Advancing Respiratory Frontiers Through Innovation, Education, and Collaboration.","authors":"Ahmad Izuanuddin Ismail, Lai Ngoh Hooi","doi":"10.1111/resp.70100","DOIUrl":"10.1111/resp.70100","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"1008-1009"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144744557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pneumothorax in Endobronchial Valve Therapy-Still a Lot to Be Learned.","authors":"T David Koster, Dirk-Jan Slebos","doi":"10.1111/resp.70086","DOIUrl":"10.1111/resp.70086","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"912-913"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Concept to Clinic: A Long-Awaited, Structured, Theory-Informed Multimodal Treatment Model for Inducible Laryngeal Obstruction.","authors":"Thomas Halvorsen, Ola Drange Røksund","doi":"10.1111/resp.70088","DOIUrl":"10.1111/resp.70088","url":null,"abstract":"","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"908-909"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Concise Review 2024: Respiratory Infections.","authors":"Naoyuki Miyashita","doi":"10.1111/resp.70113","DOIUrl":"10.1111/resp.70113","url":null,"abstract":"<p><p>Since public health measures against COVID-19 were relaxed, widespread outbreaks of respiratory infections such as influenza and respiratory syncytial virus (RSV), as well as infectious diseases transmitted by droplets and droplet nuclei, have been reported around the world. While there is evidence of antiviral drug efficacy against non-severe influenza, the emergence of two genetic mutations (I223V or S247N) that reduce susceptibility to neuraminidase inhibitors has been confirmed. Influenza vaccines are less effective in older people than in younger people; so high-dose influenza vaccines are recommended. RSV infection has a high disease burden among elderly people; however, vaccination is expected to limit or prevent severe disease. Macrolide-resistant strains of Mycoplasma species and Bordetella pertussis are common in East Asia, but an increase in resistant strains has also been observed in other Asian regions. Pneumonia in elderly people often leads to a decline in physical function. In a super-aging society, aspiration pneumonia occurs frequently. Hence, there is increasing awareness of the need for advance care planning discussions for pneumonia as well as malignant diseases. The use of inhaled steroids in bronchiectasis is not recommended because of the increased risk of infection; but in clinical practice, inhaled steroids are frequently used and are effective in some patients with bronchiectasis.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":"926-934"},"PeriodicalIF":6.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}